1. Home
  2. ATR vs DVA Comparison

ATR vs DVA Comparison

Compare ATR & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AptarGroup Inc.

ATR

AptarGroup Inc.

HOLD

Current Price

$128.35

Market Cap

9.3B

Sector

Industrials

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$150.71

Market Cap

10.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATR
DVA
Founded
1992
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Misc Health and Biotechnology Services
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3B
10.1B
IPO Year
1995
2002

Fundamental Metrics

Financial Performance
Metric
ATR
DVA
Price
$128.35
$150.71
Analyst Decision
Buy
Hold
Analyst Count
4
4
Target Price
$167.50
$156.75
AVG Volume (30 Days)
410.2K
797.3K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
1.49%
N/A
EPS Growth
6.51
N/A
EPS
5.89
9.84
Revenue
$3,777,181,000.00
$13,643,069,000.00
Revenue This Year
$5.29
$3.80
Revenue Next Year
$4.98
$3.04
P/E Ratio
$21.85
$15.57
Revenue Growth
5.42
6.46
52 Week Low
$103.23
$101.00
52 Week High
$164.28
$159.42

Technical Indicators

Market Signals
Indicator
ATR
DVA
Relative Strength Index (RSI) 35.71 57.20
Support Level $116.70 $146.00
Resistance Level $133.25 $150.69
Average True Range (ATR) 3.00 4.81
MACD -1.98 -1.40
Stochastic Oscillator 6.85 34.35

Price Performance

Historical Comparison
ATR
DVA

About ATR AptarGroup Inc.

Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Share on Social Networks: